We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparative genetic characterization of CMY-2-type beta-lactamase producing pathogenic Escherichia coli isolated from humans and pigs suffering from diarrhea in Korea.
- Authors
Seo, Kwang-Won; Do, Kyung-Hyo; Shin, Min-Kyoung; Lee, Woo-Kon; Lee, Wan-Kyu
- Abstract
Background: Pathogenic Escherichia coli are an important cause of bacterial infections in both humans and pigs and many of antimicrobials are used for the treatment of E. coli infection. The objective of this study was to investigate the characteristics and relationship between humans and pigs regarding third-generation cephalosporin resistance and CMY-2-producing E. coli in Korea. Results: All 103 third-generation cephalosporin-resistant E. coli isolates showed multidrug resistance. Also, except for β-lactam/β-lactamase inhibitor combinations, all antimicrobials resistant rates were higher in pigs than in humans. A total of 36 isolates (humans: five isolates; pigs: 31 isolates) were positive for the CMY-2-encoding genes and thirty-two (88.9%) isolates detected class 1 integrons with 10 different gene cassette arrangements, and only 1 isolate detected a class 2 integron. The most common virulence genes in pigs were LT (71.0%), F18 (51.6%), and STb (51.6%), while stx2 (80.0%) was the most frequently detected gene in humans. Stx2 gene was also detected in pigs (6.5%). Interestingly, 36 CMY-2-producing E. coli isolates showed a high diversity of sequence types (ST), and ST88 was present in E. coli from both pigs (11 isolates) and humans (one isolate). Conclusion: Our findings suggest that a critical need for comprehensive surveillance of third-generation cephalosporin resistance is necessary to preserve the usefulness of third-generation cephalosporins in both humans and pigs.
- Subjects
SOUTH Korea; BETA-lactamase inhibitors; ESCHERICHIA coli; SWINE; SWINE farms; SWINE breeding; DIARRHEA; MULTIDRUG resistance; BACTERIAL diseases
- Publication
Annals of Clinical Microbiology & Antimicrobials, 2023, Vol 22, Issue 1, p1
- ISSN
1476-0711
- Publication type
Article
- DOI
10.1186/s12941-023-00559-1